| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Payments for finance lease right-of-use asset | 8,152 | 6,791 |
| Net cash (used in) provided by financing activities | -2,917 | -2,139 |
| Net decrease in cash, cash equivalents and restricted cash | -82,466 | -32,222 |
| Cash and cash equivalents at beginning of period | 176,535 | - |
| Cash and cash equivalents at end of period | 94,069 | - |
Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Inc. (DNLI)